Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
Key takeaways
- The first positive Phase 3 mRNA cancer trial may revive the mRNA investment thesis beyond COVID and boost precision‑medicine ETFs.
- Phase 3 INTerpath‑001 trial
- Stage IIB‑IV melanoma
- Keytruda 2025 sales $31.7 billion
What happened
Moderna and Merck (MRK) announced positive Phase 3 results for intismeran, an individualized mRNA‑based neoantigen therapy, in stage IIB‑IV melanoma patients. The combination of intismeran with Merck’s Keytruda improved recurrence‑free and distant‑metastasis‑free survival versus Keytruda alone. The trial is the first successful Phase 3 readout for an individualized mRNA cancer therapy.
Why it matters
The success signals that mRNA technology can move beyond COVID vaccines into personalized oncology, potentially opening a new growth engine for both companies and the broader precision‑medicine sector. It also provides a catalyst for mRNA‑focused ETFs, which have been lagging since the pandemic peak.
Short-term and longer-term
Short-term. Short‑term traders should watch the 13% jump in IDNA and the 64% YTD gain in ARKG, as the positive trial may trigger further inflows into precision‑medicine ETFs.
Longer-term. Long‑term investors should consider the trial as a validation of mRNA’s scalability beyond vaccines, potentially expanding Merck’s oncology portfolio and creating new revenue streams for Moderna.